Novel |
PPP2R5A |
protein phosphatase 2 regulatory subunit B'alpha |
- Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
- Degradation of beta-catenin by the destruction complex
- Beta-catenin phosphorylation cascade
- Separation of Sister Chromatids
- Resolution of Sister Chromatid Cohesion
- Co-stimulation by CD28
- Co-inhibition by CTLA4
- Platelet sensitization by LDL
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Signaling by GSK3beta mutants
- CTNNB1 S33 mutants aren't phosphorylated
- CTNNB1 S37 mutants aren't phosphorylated
- CTNNB1 S45 mutants aren't phosphorylated
- CTNNB1 T41 mutants aren't phosphorylated
- APC truncation mutants have impaired AXIN binding
- AXIN missense mutants destabilize the destruction complex
- Truncations of AMER1 destabilize the destruction complex
- RHO GTPases Activate Formins
- RAF activation
- Negative regulation of MAPK pathway
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Mitotic Prometaphase
- EML4 and NUDC in mitotic spindle formation
- PKR-mediated signaling
|
|
|
Novel |
PTPN11 |
protein tyrosine phosphatase non-receptor type 11 |
- Interleukin-6 signaling
- PI3K Cascade
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- GPVI-mediated activation cascade
- Prolactin receptor signaling
- PIP3 activates AKT signaling
- Spry regulation of FGF signaling
- Signaling by SCF-KIT
- GAB1 signalosome
- Downstream signal transduction
- PECAM1 interactions
- Tie2 Signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Signaling by Leptin
- Co-inhibition by CTLA4
- Co-inhibition by PD-1
- Signal regulatory protein family interactions
- Netrin mediated repulsion signals
- Platelet sensitization by LDL
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- PI-3K cascade:FGFR1
- FRS-mediated FGFR1 signaling
- PI-3K cascade:FGFR2
- FRS-mediated FGFR2 signaling
- FRS-mediated FGFR3 signaling
- PI-3K cascade:FGFR3
- FRS-mediated FGFR4 signaling
- PI-3K cascade:FGFR4
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Regulation of IFNG signaling
- RET signaling
- Interleukin-20 family signaling
- MET activates PTPN11
- Regulation of RUNX1 Expression and Activity
- Interleukin-37 signaling
- Activated NTRK2 signals through FRS2 and FRS3
- Interferon alpha/beta signaling
- Regulation of IFNA/IFNB signaling
- Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)
- FLT3 Signaling
- STAT5 Activation
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Signaling by CSF1 (M-CSF) in myeloid cells
- STAT5 activation downstream of FLT3 ITD mutants
- Signaling by FLT3 ITD and TKD mutants
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Co-inhibition by BTLA
|
|
- Metachondromatosis
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
|
Novel |
SKP1 |
S-phase kinase associated protein 1 |
- Activation of NF-kappaB in B cells
- Prolactin receptor signaling
- SCF-beta-TrCP mediated degradation of Emi1
- Vpu mediated degradation of CD4
- SCF(Skp2)-mediated degradation of p27/p21
- Degradation of beta-catenin by the destruction complex
- Downstream TCR signaling
- NOTCH1 Intracellular Domain Regulates Transcription
- Regulation of PLK1 Activity at G2/M Transition
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling
- FCERI mediated NF-kB activation
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Dectin-1 mediated noncanonical NF-kB signaling
- CLEC7A (Dectin-1) signaling
- Degradation of GLI1 by the proteasome
- Degradation of GLI2 by the proteasome
- GLI3 is processed to GLI3R by the proteasome
- NIK-->noncanonical NF-kB signaling
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
- Orc1 removal from chromatin
- Cyclin D associated events in G1
- Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
- FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
- Regulation of RUNX2 expression and activity
- Neddylation
- Interleukin-1 signaling
- Iron uptake and transport
- Negative regulation of NOTCH4 signaling
- Regulation of BACH1 activity
- Nuclear events stimulated by ALK signaling in cancer
- GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
- Antigen processing: Ubiquitination & Proteasome degradation
- GSK3B-mediated proteasomal degradation of PD-L1(CD274)
- Degradation of CRY and PER proteins
|
- 1-naphthaleneacetic acid
- (2S)-2-(1H-indol-3-yl)hexanoic acid
- (2S)-2-(1H-indol-3-yl)pentanoic acid
- (2S)-8-[(tert-butoxycarbonyl)amino]-2-(1H-indol-3-yl)octanoic acid
- Indoleacetic acid
|
|
Novel |
STAT5A |
signal transducer and activator of transcription 5A |
- Prolactin receptor signaling
- Nuclear signaling by ERBB4
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by SCF-KIT
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- Signaling by Leptin
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-20 family signaling
- Interleukin-15 signaling
- Interleukin-9 signaling
- Interleukin-2 signaling
- Interleukin-2 signaling
- Interleukin-21 signaling
- Erythropoietin activates STAT5
- STAT5 Activation
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by CSF3 (G-CSF)
- STAT5 activation downstream of FLT3 ITD mutants
- Signaling by FLT3 fusion proteins
- Inactivation of CSF3 (G-CSF) signaling
- Nuclear events stimulated by ALK signaling in cancer
- Growth hormone receptor signaling
- Growth hormone receptor signaling
|
|
|
Novel |
STAT5B |
signal transducer and activator of transcription 5B |
- Prolactin receptor signaling
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by SCF-KIT
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- Signaling by Leptin
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-20 family signaling
- Interleukin-15 signaling
- Interleukin-9 signaling
- Interleukin-2 signaling
- Interleukin-2 signaling
- Interleukin-21 signaling
- Erythropoietin activates STAT5
- STAT5 Activation
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by CSF3 (G-CSF)
- STAT5 activation downstream of FLT3 ITD mutants
- Signaling by FLT3 fusion proteins
- Inactivation of CSF3 (G-CSF) signaling
- Growth hormone receptor signaling
- Growth hormone receptor signaling
|
|
- Growth hormone insensitivity with immunodeficiency
|
Novel |
TMEM218 |
transmembrane protein 218 |
|
|
|
Novel |
TXK |
TXK tyrosine kinase |
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
|
- Fostamatinib
- Zanubrutinib
|
|
|
AOX1 |
aldehyde oxidase 1 |
- Vitamin B6 activation to pyridoxal phosphate
|
- Cyclobenzaprine
- Eniluracil
|
|
|
AP1M1 |
adaptor related protein complex 1 subunit mu 1 |
- Nef mediated downregulation of MHC class I complex cell surface expression
- MHC class II antigen presentation
- Lysosome Vesicle Biogenesis
- Golgi Associated Vesicle Biogenesis
- Neutrophil degranulation
|
|
|
|
AP2M1 |
adaptor related protein complex 2 subunit mu 1 |
- Nef mediated downregulation of CD28 cell surface expression
- Nef Mediated CD4 Down-regulation
- Retrograde neurotrophin signalling
- Retrograde neurotrophin signalling
- Nef Mediated CD8 Down-regulation
- Gap junction degradation
- Formation of annular gap junctions
- MHC class II antigen presentation
- EPH-ephrin mediated repulsion of cells
- Recycling pathway of L1
- Recycling pathway of L1
- WNT5A-dependent internalization of FZD4
- WNT5A-dependent internalization of FZD2, FZD5 and ROR2
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- VLDLR internalisation and degradation
- LDL clearance
- Potential therapeutics for SARS
|
|
|
|
ATP5MC3 |
ATP synthase membrane subunit c locus 3 |
- Formation of ATP by chemiosmotic coupling
- Cristae formation
|
|
|
|
BCS1L |
BCS1 ubiquinol-cytochrome c reductase complex chaperone |
- Mitochondrial protein import
- Complex III assembly
|
|
- Bjornstad syndrome
- Mitochondrial respiratory chain deficiencies (MRCD), including: Mitochondrial complex I deficiency (MT-C1D); Complex II deficiency (MT-C2D); Complex III deficiency (MT-C3D); Complex IV deficiency (MT-C4D); Complex V deficiency (MT-ATPSD); Leigh syndrome (LS); Kearns-Sayre Syndrome (KSS); LCHD deficiency (LCHD); Leber Hereditary Optic Neuropathy (LHON); Myoclonic Epilepsy and Ragged-Red Fiber Disease (MERRF); NARP; MELAS; ACAD9 deficiency; HADH deficiency; HIBCH deficiency; GRACILE syndrome
|
|
CD28 |
CD28 molecule |
- PIP3 activates AKT signaling
- Nef mediated downregulation of CD28 cell surface expression
- Constitutive Signaling by Aberrant PI3K in Cancer
- Co-stimulation by CD28
- CD28 dependent PI3K/Akt signaling
- CD28 dependent Vav1 pathway
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
|
|
|
CD80 |
CD80 molecule |
- PIP3 activates AKT signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Co-stimulation by CD28
- CD28 dependent PI3K/Akt signaling
- CD28 dependent Vav1 pathway
- Co-inhibition by CTLA4
- Interleukin-10 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
- Abatacept
- Galiximab
- Belatacept
|
|
|
CD86 |
CD86 molecule |
- PIP3 activates AKT signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Co-stimulation by CD28
- CD28 dependent PI3K/Akt signaling
- CD28 dependent Vav1 pathway
- Co-inhibition by CTLA4
- Interleukin-10 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
- Antithymocyte immunoglobulin (rabbit)
- Abatacept
- Belatacept
- Bryostatin 1
|
|
|
CDC26 |
cell division cycle 26 |
- Inactivation of APC/C via direct inhibition of the APC/C complex
- APC/C:Cdc20 mediated degradation of Cyclin B
- Autodegradation of Cdh1 by Cdh1:APC/C
- APC/C:Cdc20 mediated degradation of Securin
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Cdc20:Phospho-APC/C mediated degradation of Cyclin A
- Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
- Regulation of APC/C activators between G1/S and early anaphase
- APC/C:Cdc20 mediated degradation of mitotic proteins
- Phosphorylation of the APC/C
- APC-Cdc20 mediated degradation of Nek2A
- Separation of Sister Chromatids
- Senescence-Associated Secretory Phenotype (SASP)
- Assembly of the pre-replicative complex
- CDK-mediated phosphorylation and removal of Cdc6
- Transcriptional Regulation by VENTX
- Aberrant regulation of mitotic exit in cancer due to RB1 defects
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
CLK1 |
CDC like kinase 1 |
|
- Debromohymenialdisine
- CHGN111
- ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate
- Fostamatinib
|
|
|
CTXN3 |
cortexin 3 |
|
|
|
|
DCTD |
dCMP deaminase |
- Interconversion of nucleotide di- and triphosphates
|
|
|
|
FYN |
FYN proto-oncogene, Src family tyrosine kinase |
- GPVI-mediated activation cascade
- Signaling by ERBB2
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Nef and signal transduction
- Cell surface interactions at the vascular wall
- FCGR activation
- PECAM1 interactions
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- DAP12 signaling
- EPH-Ephrin signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Nephrin family interactions
- Nephrin family interactions
- NCAM signaling for neurite out-growth
- NCAM signaling for neurite out-growth
- Co-stimulation by CD28
- CD28 dependent PI3K/Akt signaling
- CD28 dependent Vav1 pathway
- Co-inhibition by CTLA4
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- EPHA-mediated growth cone collapse
- Ephrin signaling
- Ephrin signaling
- EPH-ephrin mediated repulsion of cells
- Sema3A PAK dependent Axon repulsion
- SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
- SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
- CRMPs in Sema3A signaling
- CRMPs in Sema3A signaling
- VEGFA-VEGFR2 Pathway
- Dectin-2 family
- CD209 (DC-SIGN) signaling
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Platelet Adhesion to exposed collagen
- Reelin signalling pathway
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- FCGR3A-mediated IL10 synthesis
- FCGR3A-mediated phagocytosis
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by CSF1 (M-CSF) in myeloid cells
- FLT3 signaling through SRC family kinases
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
|
- Dasatinib
- Triglyme
- Fostamatinib
- Zotiraciclib
|
|